Literature DB >> 1505300

High systolic blood pressure increases prevalence and severity of retinopathy in NIDDM patients.

M Cignarelli1, M L De Cicco, A Damato, A Paternostro, S Pagliarini, S Santoro, L Cardia, G De Pergola, R Giorgino.   

Abstract

OBJECTIVE: To determine whether the severity of retinopathy is higher in a group of NIDDM patients with sBP greater than or equal to 140 mmHg compared with NIDDM patients with sBP less than 140 mmHg. RESEARCH DESIGN AND METHODS: Ophthalmoscopy and FAG were conducted among a group of NIDDM patients with either a sBP above (n = 54) or below (n = 55) 140 mmHg. The groups were matched according to diabetes duration, metabolic control (HbA1c), and AER.
RESULTS: Patients with sBP greater than 140 mmHg had a higher prevalence of retinopathy, as established according to a rating scale (4.9 +/- 3.8 vs. 3.2 +/- 3.3, P less than 0.02); furthermore, their BMI values were higher (28.1 +/- 4.5 vs. 24.9 +/- 4.1 kg/m2, P less than 0.001). The group of normotensive subjects showed the highest rate of low grading (0-2) values. However, the highest prevalence rates of 8-10 grading values (proliferative retinopathy) were found in the hypertensive group.
CONCLUSIONS: These data suggest that sBP values greater than or equal to 140 mmHg favor the onset of retinopathy in NIDDM patients during their 1st 10 yr of disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1505300     DOI: 10.2337/diacare.15.8.1002

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  11 in total

1.  Macular circulation in patients with diabetes mellitus with and without arterial hypertension.

Authors:  O Arend; M Rüffer; A Remky
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

Review 2.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 3.  New concepts in diabetes mellitus. II: Complications.

Authors:  M Vanderpump; R Taylor
Journal:  Postgrad Med J       Date:  1994-07       Impact factor: 2.401

4.  Pretreatment clinical variables associated with the response to intravitreal bevacizumab (Avastin) injection in patients with persistent diabetic macular edema.

Authors:  Fareed A Warid Al-Laftah; Maha Elshafie; Mustafa Alhashimi; Aant Pai; Mohammad Farouq
Journal:  Saudi J Ophthalmol       Date:  2010-05-25

5.  Diabetic retinopathy in Down's syndrome.

Authors:  T Fulcher; M Griffin; S Crowley; R Firth; R Acheson; N O'Meara
Journal:  Br J Ophthalmol       Date:  1998-04       Impact factor: 4.638

6.  Prevalence of diabetic retinopathy in screening-detected diabetes mellitus: results from the Gutenberg Health Study (GHS).

Authors:  Katharina A Ponto; Jochem Koenig; Tunde Peto; Julia Lamparter; Philipp Raum; Philipp S Wild; Karl J Lackner; Norbert Pfeiffer; Alireza Mirshahi
Journal:  Diabetologia       Date:  2016-06-17       Impact factor: 10.122

7.  Albuminuria and Diabetic Retinopathy in Type 2 Diabetes Mellitus Sankara Nethralaya Diabetic Retinopathy Epidemiology And Molecular Genetic Study (SN-DREAMS, report 12).

Authors:  Padmaja K Rani; Rajiv Raman; Aditi Gupta; Swakshyar S Pal; Vaitheeswaran Kulothungan; Tarun Sharma
Journal:  Diabetol Metab Syndr       Date:  2011-05-25       Impact factor: 3.320

8.  Hypertension in diabetics registered in primary health care centers in makkah district, saudi arabia.

Authors:  A G Elzubier
Journal:  J Family Community Med       Date:  2000-09

9.  Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study.

Authors:  Patricia Herold Gallego; Maria E Craig; Stephen Hing; Kim C Donaghue
Journal:  BMJ       Date:  2008-08-26

10.  Four-year incidence of diabetic retinopathy in a Spanish cohort: the MADIABETES study.

Authors:  Miguel Á Salinero-Fort; Francisco Javier San Andrés-Rebollo; Carmen de Burgos-Lunar; Francisco Jesús Arrieta-Blanco; Paloma Gómez-Campelo
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.